

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 91455

Title: Advancements in Medical Treatment for Pancreatic Neuroendocrine Tumors: A

Beacon of Hope

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03202632 Position: Peer Reviewer Academic degree: PhD

Professional title: Professor

Reviewer's Country/Territory: China

Author's Country/Territory: India

Manuscript submission date: 2023-12-28

Reviewer chosen by: Huo Liu

Reviewer accepted review: 2024-01-16 14:24

Reviewer performed review: 2024-01-16 15:09

Review time: 1 Hour

	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair
this manuscript	[] Grade D: No creativity or innovation



Baishideng

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 E-mail: office@baishideng.com

https://www.wjgnet.com

[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair
[] Grade D: No scientific significance
[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
[] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
[]Yes [Y]No
Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The manuscript titled "Advancements in Medical Treatment for Pancreatic Neuroendocrine Tumors: A Beacon of Hope" provides a comprehensive overview of the current advancements in medical treatment strategies for pancreatic neuroendocrine tumors (Pan-NETs). The authors emphasize the importance of tailored approaches based on tumor subtypes and highlight the pivotal role of cytoreductive surgery and somatostatin analogues (SSAs) in managing these tumors. They also discuss palliative options such as molecular targeted therapy, peptide receptor radionuclide therapy, and chemotherapy for SSA-refractory cases. The review underscores the evolving landscape of Pan-NET treatment and explores promising avenues for future research in the field.